Tag: Novartis Pharmaceuticals Corporation

Sandostatin, Celebrating 25 Years of Commitment

Novartis Offers New Sandostatin LAR Depot Co-Pay Assistance Program

March 31, 2014

A new co-pay assistance program for carcinoid syndrome patients taking Sandostatin® LAR Depot has been established by Novartis Pharmaceuticals Corporation, effective February 2014.

With the Sandostatin® LAR Depot Co-Pay Assistance Program, eligible…

READ MORE
My NET Manager Mobile App for Carcinoid Cancer and Neuroendocrine Tumor Community

First Mobile App for Carcinoid and Neuroendocrine Cancer Community Goes Live

June 15, 2012

The first mobile app for carcinoid cancer and neuroendocrine tumor (NET) patients is now available for downloading on the iPhone, iPad, and Android!  My NET Manager, a free app provided by Novartis Oncology, offers patients a unique opportunity to track…

READ MORE
Jan Naritomi-Hart

10 Highlights of the Year 2011 for the Carcinoid and Neuroendocrine Tumor Community

December 15, 2011

As the Carcinoid Cancer Foundation looks back on the year 2011, there were many significant events and advances for the carcinoid and neuroendocrine tumor (NET) community.  Here are 10 of the year’s important stories:

1)     The FDA approved the first…

READ MORE
Siemens’ Biograph mMR system

Up-to-the-Minute: News for the Carcinoid and Neuroendocrine Tumor Community

June 12, 2011

The first device that simultaneously performs PET and MRI scans, a new alpha-emitter-based therapy for NET cancer patients with progressive therapy-resistant tumors, the first–ever randomized virtual clinical trial, over 100  abstracts on carcinoid

READ MORE
Novartis logo

Breaking News: FDA Approves Treatment for pNET Patients

May 5, 2011

For the first time in nearly three decades, there is a new treatment for pancreatic neuroendocrine tumor patients!  The Food and Drug Administration (FDA) today announced its approval of Afinitor© for pNET patients.  This is a milestone for the carcinoid/NET…

READ MORE
FDA logo

Carcinoid Cancer Foundation to Speak on Behalf of NET Cancer Patients at April 12, 2011 FDA Oncologic Drugs Advisory Committee Meeting

March 24, 2011

Grace Goldstein, Chief Operating Officer of the Carcinoid Cancer Foundation, will speak at the Open Public Hearing segment during the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee Meeting on April 12, 2011 in Silver …

READ MORE
iWalk for Carcinoid

iWalk for Carcinoid

September 25, 2010

iWalk for Carcinoid is a virtual walkathon to help raise money for carcinoid-related organizations. The Carcinoid Cancer Foundation is one of the organizations selected to benefit from this virtual walkathon.  Each organization has the opportunity…

READ MORE